Gender & Sex Development Program, Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Pritzker Department of Psychiatry and Behavioral Health, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Child & Adolescent Gender Center, Benioff Children's Hospital, University of California, San Francisco, California; Division of Pediatric Endocrinology, Department of Pediatrics, University of California San Francisco, San Francisco, California.
J Adolesc Health. 2021 Jun;68(6):1104-1111. doi: 10.1016/j.jadohealth.2020.07.033. Epub 2020 Aug 21.
This study aimed to characterize two developmental cohorts of transgender and nonbinary youth enrolled in the Trans Youth Care Network Study and describe their gender identity-related milestones and baseline mental health and psychosocial functioning.
Trans Youth Care participants were recruited from four pediatric academic medical centers in the U.S. before initiating medical treatment for gender dysphoria either with gonadotropin-releasing hormone agonists (GnRHa) or gender-affirming hormones (GAH). GnRHa cohort data were collected from youth and a parent; GAH cohort data were collected from youth only.
A total of 95 youth were enrolled in the GnRHa cohort. Mean age was 11.22 years (standard deviation = 1.46), and the majority were white (52.6%) and designated male at birth (51.6%). Elevated depression symptoms were endorsed by 28.6% of GnRHa cohort youth, and 22.1% endorsed clinically significant anxiety. Approximately one fourth (23.6%) endorsed lifetime suicidal ideation, with 7.9% reporting a past suicide attempt. A total of 316 youth were enrolled in the GAH cohort. The mean age was 16.0 years (standard deviation = 1.88), and the majority were white (62%) and designated female at birth (64.9%). Elevated depression symptoms were endorsed by 51.3% of the GAH cohort, and 57.3% endorsed clinically significant anxiety. Two-thirds (66.6%) endorsed lifetime suicidal ideation, with 24.6% reporting a past suicide attempt. Life satisfaction was lower among both cohorts compared with population-based norms.
GnRHa cohort youth appear to be functioning better from a psychosocial standpoint than GAH cohort youth, pointing to possible benefits of accessing gender-affirming treatment earlier in life.
本研究旨在描述参加跨青年护理网络研究的跨性别和非二元青年的两个发展队列，并描述他们与性别认同相关的里程碑以及基线心理健康和心理社会功能。
在开始因性别焦虑症接受促性腺激素释放激素激动剂（GnRHa）或性别肯定激素（GAH）治疗之前，跨青年护理参与者从美国的四家儿科学术医疗中心招募。GnRHa 队列的数据是从青少年及其父母收集的；GAH 队列的数据仅从青少年收集。
共有 95 名青少年参加了 GnRHa 队列。平均年龄为 11.22 岁（标准差=1.46），大多数是白人（52.6%），出生时被指定为男性（51.6%）。28.6%的 GnRHa 队列青少年有抑郁症状，22.1%的青少年有临床显著的焦虑症。大约四分之一（23.6%）的青少年有过自杀念头，其中 7.9%的青少年有过自杀企图。共有 316 名青少年参加了 GAH 队列。平均年龄为 16.0 岁（标准差=1.88），大多数是白人（62%），出生时被指定为女性（64.9%）。51.3%的 GAH 队列青少年有抑郁症状，57.3%的青少年有临床显著的焦虑症。三分之二（66.6%）的青少年有过自杀念头，其中 24.6%的青少年有过自杀企图。与基于人群的标准相比，两个队列的生活满意度都较低。
GnRHa 队列的青少年在心理社会方面的功能似乎比 GAH 队列的青少年更好，这表明在生命早期获得性别肯定治疗可能会有好处。
